Abivax (ABVX) Debt Ratio (2021 - 2026)

Abivax (ABVX) posted quarterly Debt Ratio of 0.0 for Q1 2026, down 99.52% year-over-year from 0.42 in Q1 2025, and down 54.84% quarter-over-quarter from 0.0 in Q4 2025.

Abivax (ABVX) Debt Ratio (2021 - 2026) Analysis & Trends

Abivax's Debt Ratio history runs 6 years deep, the most recent figure standing at 0.0 for Q1 2026.

  • In Q1 2026, Debt Ratio fell 99.52% year-over-year to 0.0; the TTM figure through Mar 2026 stood at 0.0 (down 99.52% YoY), while the FY2025 annual figure was 0.0, down 99.2% from the prior year.
  • Debt Ratio for Q1 2026 stood at 0.0, down from 0.0 in the prior quarter.
  • The five-year high for Debt Ratio was 0.66 in Q4 2022, with the low at 0.0 in Q1 2026.
  • The 5-year median for Debt Ratio is 0.24 (2023), against an average of 0.3.
  • The sharpest annual moves came in 2025 and 2026: Debt Ratio jumped 334.08% in 2025, then sank 99.52% in 2026.
  • Abivax's Debt Ratio stood at 0.66 in 2022, then plunged by 64.26% to 0.24 in 2023, then soared by 135.85% to 0.56 in 2024, then sank by 99.2% to 0.0 in 2025, then sank by 54.84% to 0.0 in 2026.
  • Business Quant data shows ABVX's Debt Ratio at 0.0 in Q1 2026, 0.0 in Q4 2025, and 0.08 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.05
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 0.12
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 0.47
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 0.26
10 Abivax 9.39 Bn 9.39 Bn - 0.00

Historic Data

Download Data
DateValue
Mar 31, 2026 0.00
Dec 31, 2025 0.00
Sep 30, 2025 0.08
Jun 30, 2025 0.63
Mar 31, 2025 0.42
Dec 31, 2024 0.56
Jun 30, 2024 0.14
Dec 31, 2023 0.24
Dec 31, 2022 0.66
Dec 31, 2021 0.56